Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer

European Urology

Volumn 57, Issue 4, 2010, Pages 631-640

  Ladjevardi, Sam ^a   Sandblom, Gabriel ^b   Berglund, Anders ^a   Varenhorst, Eberhard ^c  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Conservative management; Curative management; Epidemiology; Prostate cancer; Radical prostatectomy; Radiotherapy

Indexed keywords

ANTIANDROGEN; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; COHORT ANALYSIS; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SWEDEN; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; WATCHFUL WAITING;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CELL DIFFERENTIATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PALLIATIVE CARE; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; SWEDEN; TIME FACTORS; TREATMENT OUTCOME; WATCHFUL WAITING;

EID: 77249085191     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.03.007     Document Type: Article

References (23)

1. Bill-Axelson A., Holmberg L., Filén F., et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer Group-4 randomized trial. J Natl Cancer Inst 100 (2008) 1144-1154
2. Klotz L. Active surveillance versus radical treatment for favorable-risk localized prostate cancer. Curr Treat Options Oncol 7 (2006) 355-362
3. Roemeling S., Roobol M.J., Postma R., et al. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. Eur Urol 50 (2006) 475-482
4. Sandblom G., Ladjevardi S., Garmo H., and Varenhorst E. The impact of prostate-specific antigen level at diagnosis on the relative survival of 28,531 men with localized carcinoma of the prostate. Cancer 112 (2008) 813-819
5. Varenhorst E., Garmo H., Holmberg L., et al. The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival. Scand J Urol Nephrol 39 (2005) 117-123
6. Cancer incidence in Sweden 2006. Regionalt Onkologiskt Centrum Web site [in Swedish]. http://www.roc.se/cancerstat.asp. Accessed 27 June 2008.
7. Sandblom G., Dufmats M., Olsson M., and Varenhorst E. Validity of a population-based cancer register in Sweden-an assessment of data reproducibility in the South-East Region Prostate Cancer Register. Scand J Urol Nephrol 37 (2003) 112-119
8. Population registration in Sweden. Skatteverket Web site. http://www.skatteverket.se/blanketterbroschyrer/broschyr/info/717b.4.39f16f103821c58f680008017.html. Accessed 9 July 2008.
9. Sobin L.H. TNM, sixth edition: new developments in general concepts and rules. Semin Surg Oncol 21 (2003) 19-22
10. Dickman P.W., Slogett A., Hills M., and Hakulinen T. Regression models for relative survival. Stat Med 23 (2004) 51-64
11. Statistikdatabasen [population statistics]. Statistics Sweden Web site [in Swedish]. http://www.ssd.scb.se. Accessed 27 June 2008.
12. Murphy G.P., Busch C., Abrahamsson P.A., et al. Histopathology of localized prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993. Scand J Urol Nephrol Suppl 162 (1994) 7-42
13. Aus G., Abbou C.C., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 48 (2005) 546-551
14. Holmberg L., Bill-Axelson A., Helgesen F., et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347 (2002) 781-789
15. Amling C.L., Blute M.L., Lerner S.E., Bergstralh E.J., Bostwick D.G., and Zincke H. Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin Proc 73 (1998) 401-406
16. Perrotti M., Rabbani F., Farkas A., Ward W.S., and Cummings K.B. Trends in poorly differentiated prostate cancer 1973 to 1994: observations from the Surveillance. Epidemiology and End Results database. J Urol 160 (1998) 811-815
17. Tefilli M.V., Gheiler E.L., Tiguert R., et al. Role of radical prostatectomy in patients with prostate cancer of high Gleason score. Prostate 39 (1999) 60-66
18. Zincke H., Oesterling J.E., Blute M.L., Bergstralh E.J., Myers R.P., and Barrett D.M. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 152 (1994) 1850-1857
19. Grossfeld G.D., Latini D.M., Lubeck D.P., Mehta S.S., and Carroll P.R. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol 169 (2003) 157-163
20. Boer R, Ries L, Ballegooijen V, Feuer EJ, Legler J, Habbema D; National Cancer Institute. Ambiguities in calculating cancer patient survival: the SEER experience for colorectal and prostate cancer. http://srab.cancer.gov/reports/tech2003.05.pdf. Published 2002. Accessed 23 December 2008.
21. Tward J.D., Lee C.M., Pappas L.M., Szabo A., Gaffney D.K., and Shrieve D.C. Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment: impact of age at diagnosis. Cancer 107 (2006) 2392-2400
22. Tewari A., Divine G., Chang P., et al. Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy-a propensity scoring approach. J Urol 177 (2007) 911-915
23. Thompson I., Thrasher J.B., Aus G., et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177 (2007) 2106-2131